Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

Y0000733

Dacarbazine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide, DTIC

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H10N6O
Numéro CAS:
4342-03-4
Poids moléculaire :
182.18
Numéro MDL:
MFCD00057167
Code UNSPSC :
41116107
ID de substance PubChem :
329831122
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

dacarbazine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CN(C)\N=N\c1[nH]cnc1C(N)=O

InChI

1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+

Clé InChI

FDKXTQMXEQVLRF-ZHACJKMWSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dacarbazine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000734

Dacarbazine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000735

Dacarbazine impurity B, European Pharmacopoeia (EP) Reference Standard

1162320

Dacarbazine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1162330

Dacarbazine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1162308

Dacarbazine, United States Pharmacopeia (USP) Reference Standard

BP100

Dacarbazine, British Pharmacopoeia (BP) Reference Standard

BP024

2-Azahypoxanthine, British Pharmacopoeia (BP) Reference Standard

PHR2304

Dacarbazine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation mark
GHS08,GHS07

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

O Mizuno
Nihon Naibunpi Gakkai zasshi, 70(9), 1039-1046 (1994-11-20)
A 49-year-old woman had a right adrenalectomy for pheochromocytoma in April 1989. In May 1990 she underwent an operation to remove paraaortic lymph nodes, and the lymph nodes showed pheochromocytoma. Twenty-two months after the first operation, metastases to the left
[Dacarbazine].
M D'incan et al.
Annales de dermatologie et de venereologie, 128(4), 517-525 (2001-06-08)
Annette E Hay et al.
Hematology/oncology clinics of North America, 28(1), 49-63 (2013-11-30)
Because long-term survival of patients with nonbulky stage IA to IIA Hodgkin lymphoma is dependent on disease control and avoidance of late toxic effects associated with the treatment received, the initial choice of treatment can be associated with trade-offs that
Kamila Koprowska et al.
Postepy higieny i medycyny doswiadczalnej (Online), 65, 734-751 (2011-12-17)
Melanoma is a tumour derived from melanocytes, cells of neuroectodermal origin. Melanoma treatment represents a challenge to oncologists due to its aggressive course and early and multiple metastases. Surgical excision of lesions is a highly effective intervention, but only in
Chelsea Ma et al.
The Journal of dermatological treatment, 25(5), 401-408 (2013-06-15)
Current immunomodulatory agents for stage III and IV melanoma exert different mechanisms of action that manifest in distinct adverse events. This systematic review aims to synthesize safety data from clinical trials on ipilimumab, vemurafenib, interferon (IFN) alfa-2b, dacarbazine and interleukin
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique